Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Y. Suzuki is active.

Publication


Featured researches published by Y. Suzuki.


European Urology Supplements | 2012

922 Incidence and oncological outcome of renal cell carcinoma in hemodialysis patients detected by annual computed tomography (CT) screening

S. Hatakeyama; Y. Suzuki; Hayato Yamamoto; S. Kudo; T. Yoneyama; Takuya Koie; N. Kamimura; H. Saitoh; Tomihisa Funyu; Chikara Ohyama

426 Background: Patients with maintenance hemodialysis (HD) have been recognized as a high risk group for cancer. The aim of this study was to verify the incidence and oncological outcomes of patients on maintenance hemodialysis with renal cell carcinoma (RCC) compared with RCC patients without renal dysfunction. METHODS We have been carried out annual screening for renal mass for the hemodialysis patients.The oncological outcome of pT1N0M0 RCC detected by annual screening of CT imaging were retrospectively reviewed in 1217 patients with HD between January 2002 and December 2010 at Oyokyo kidney Research Institute and Hirosaki University Hospital, Hirosaki, Japan. Overall and cancer specific survival was compared with age matched 106 of pT1N0M0 RCC patients without renal dysfunction who performed radical nephrectomy at the same periods. RESULTS Among the hemodialysis patients, 14 RCCs were incidentally detected by screening CT examinations and RCC detection rate in HD patients was 0.27% per year. Total 119 pT1N0M0 RCC patients (13 with HD group, 106 normal kidney function group) were incidentally detected by regular abdominal CT imaging without symptoms. There were no significant differences on age and gender between HD and normal kidney function group. Cancer specific survival after tumor diagnosis was not different, but overall survivals were significantly superior in patients without renal dysfunction compared to those with chronic renal failure (P < 0.0001). Cancer specific and Overall 5-year survival was 95% and 96% in patients without renal dysfunction, 92% and 54% in those with chronic renal failure. CONCLUSIONS There was no significant difference in cancer specific survival of pT1 RCC between the two groups. However, overall survival was significantly worse in HD patients. Oncological effectiveness of annual CT screening for the HD patients was not evident in the present retrospective study.


European Urology Supplements | 2013

79 Sequential chemotherapy with gemcitabine plus carboplatin followed by additional docetaxel for aged patients with advanced bladder cancer

T. Yoneyama; Y. Suzuki; N. Sugiyama; Hayato Yamamoto; A. Okamoto; Y. Tobisawa; Atsushi Imai; Kazuyuki Mori; S. Hatakeyama; Yasuhiro Hashimoto; Takuya Koie; Chikara Ohyama


European Urology Supplements | 2013

602 Blood group antigen-targeting peptide suppresses anti-blood group antibody binding to antigen in renal glomerular capillaries after ABO-incompatible blood reperfusion

T. Yoneyama; S. Hatakeyama; Y. Tobisawa; Hayato Yamamoto; Kengo Imanishi; T. Okamoto; Noriko Tokui; N. Sugiyama; Y. Suzuki; S. Kudo; Yasuhiro Hashimoto; Takuya Koie; N. Kamimura; M. Fukuda; Chikara Ohyama


European Urology Supplements | 2013

463 Anti-hypertensive effect of laparoscopic adrenalectomy (LA) for the patients with primary aldosteronism (PA) is limited despite of the accurate determination of responsible lesion by adrenal venous sampling (AVS)

Hayato Yamamoto; S. Hatakeyama; N. Sugiyama; Y. Suzuki; A. Okamoto; Atsushi Imai; T. Yoneyama; Yasuhiro Hashimoto; Takuya Koie; T. Nigawara; K. Terui; S. Sakihara; Chikara Ohyama


European Urology Supplements | 2012

867 Neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer: A propensity score analysis

Takuya Koie; T. Okamoto; Y. Suzuki; Y. Tobisawa; T. Yoneyama; Kazuyuki Mori; Hayato Yamamoto; S. Hatakeyama; S. Kudoh; N. Kamimura; Chikara Ohyama


European Urology Supplements | 2012

647 Fer kinase regulates prostate cancer cell migration through α-dystroglycan glycosylation

T. Yoneyama; K. Angata; B. Xingfeng; S. Hatakeyama; Y. Tobisawa; Kazuyuki Mori; Hayato Yamamoto; Kengo Imanishi; Noriko Tokui; T. Okamoto; N. Sugiyama; Y. Suzuki; S. Kudo; Takuya Koie; N. Kamimura; Chikara Ohyama; S. Chanda; M. Fukuda


European Urology Supplements | 2011

377 BLOCKING OF BLOOD GROUP A- OR B-ANTIGEN BY BLOOD GROUP SPECIFIC BINDING PEPTIDE: NEW STRATEGY BY OVERCOMING ABO INCOMPATIBLE KIDNEY TRANSPLANTATION

T. Yoneyama; S. Hatakeyama; Kengo Imanishi; Noriko Tokui; T. Okamoto; N. Sugiyama; Y. Suzuki; S. Kudo; Takuya Koie; N. Kamimura; Chikara Ohyama


European Urology Supplements | 2011

621 EXPRESSION OF LAMININ-BINDING GLYCANS ON ALPHA-DYSTROGLYCAN CORRELATES WITH TUMOR SUPPRESSOR FUNCTION IN PROSTATE CANCER

S. Hatakeyama; X. Bao; Y. Ishibashi; H. Murasawa; Noriko Tokui; T. Okamoto; Kengo Imanishi; Y. Suzuki; N. Sugiyama; Hayato Yamamoto; S. Kudo; T. Yoneyama; Takuya Koie; N. Kamimura; Chikara Ohyama; M. Fukuda


European Urology Supplements | 2010

720 I CORE 2 N-ACETYLGLUCOSAMINYLTRANSFERASE-1 (C2GNT-1) EXPRESSION INDUCES AGGRESSIVE POTENTIAL OF TESTICULAR GERM CELL TUMOUR

S. Hatakevama; A. Kyan; Hayato Yamamoto; A. Okamoto; N. Sugiyama; Y. Suzuki; Kengo Imanishi; T. Okamoto; S. Kudo; T. Yoneyama; Y. Hashimto; Takuya Koie; N. Kamimura; Chikara Ohyama


European Urology Supplements | 2010

858 CORE3 O-GLYCAN SYNTHASE SUPPRESSES TUMOUR FORMATION AND METASTASIS OF PROSTATE CARCINOMA PC3 AND LNCAP CELLS THROUGH DOWN-REGULATION OF α2β1 INTEGRIN COMPLEX

S. Hatakevama; S.H. Lee; Hayato Yamamoto; A. Okamoto; T. Okamoto; Kengo Imanishi; Y. Suzuki; N. Sugiyama; S. Kudo; T. Yoneyama; Y. Hashimto; Takuya Koie; N. Kamimura; Chikara Ohyama; M. Fukuda

Collaboration


Dive into the Y. Suzuki's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge